SCHEMBL7657174

SCHEMBL7657174

NC1CN(c2ccccc2)c2ccccc2NC1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.42
MAPT P10636 4/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
DDB1 Q16531 2/20 0.38
CRBN Q96SW2 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
DPP4 P27487 1/20 0.38
G6PD P11413 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
ADORA3 P0DMS8 1/20 0.36
CHRM1 P11229 1/20 0.36
EPHX2 P34913 1/20 0.36
POLB P06746 2/20 0.35
HTT P42858 1/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7657163 1.00 GAA (0.42) GAAMAPTKDM4EALDH1A1DDB1
SCHEMBL20580064 1.00 GAA (0.42) GAAMAPTKDM4EALDH1A1DDB1
Bromide SCHEMBL6178391 0.98 GAA (0.41) GAAMAPTKDM4EALDH1A1DDB1
SCHEMBL15628122 0.89 MEN1 (0.40) GAAMAPTKDM4EALDH1A1DPP4
SCHEMBL15628080 0.89 MAPT (0.39) GAAMAPTKDM4EALDH1A1ADORA3
SCHEMBL15628126 0.86 HTR7 (0.40) GAAMAPTKDM4EALDH1A1KMT2A
SCHEMBL15628087 0.84 DPP4 (0.39) GAAMAPTKDM4EDDB1CRBN
SCHEMBL20580336 0.84 ALDH1A1 (0.37) GAAMAPTKDM4EALDH1A1KMT2A
SCHEMBL20580338 0.84 ALDH1A1 (0.37) GAAMAPTKDM4EALDH1A1KMT2A
SCHEMBL15628123 0.83 HTR6 (0.45) GAAMAPTKDM4EALDH1A1DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752598-B2 Aryldiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-08-25 US disclosed
WO-2018226801-A1 ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2018-12-13 WO disclosed
US-20180354912-A1 ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2018-12-13 US disclosed
US-6344452-B1 GASTRIN RECEPTOR ANTAGONIST, GASTROINTESTINAL DISORDERS, ETC ZERIA PHARMACEUTICALS CO., LTD. (JP) 2002-02-05 US disclosed
EP-1085014-A1 1,5-BENZODIAZEPINE DERIVATIVES Zeria Pharmaceutical Co., Ltd. (JP) 2001-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180354912-A1 ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS AHR, FURIN, CYP3A5 GAA 1415/4885MAPT 3156/4885KDM4E 544/4885
US-10752598-B2 Aryldiazepine derivatives as RSV inhibitors AHR, FURIN, CYP3A5 GAA 1415/4885MAPT 3156/4885KDM4E 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.